Population Health Strategies to Avoid Mortality Associated with Albuminuria

Improving awareness of CKD as a cardiovascular risk factor at the system and payer level requires integrating kidney markers—uACR and eGFR—into routine risk algorithms, quality metrics, and population health dashboards. Programs emphasizing standardized screening, clinician education, and care-gap alerts have been especially effective. Strong evidence shows that higher albuminuria is independently associated with increased cardiovascular mortality, while declining eGFR further elevates risk through toxin accumulation, neurohormonal activation, and hemodynamic stress. Early diagnosis of both markers is essential: identifying abnormalities before symptoms emerge allows timely initiation of reno- and cardioprotective therapies, helping slow disease progression, reduce acute cardiovascular events, and improve long-term survival.